Satraplatin in Hormone-Refractory Prostate Cancer and Other Tumour Types

Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005 Apr; 4 (4): 307–20 Hartwig JF, Lippard SJ. DNA binding properties of cis-[Pt(NH3)(C6H11NH2)Cl2], a metabolite of an orally active platinum anticancer drug. J Am Chem Soc 1992 Jul; 114 (14): 5646–54 Vaisman A, Lim S, Patrick SM, et al. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity of translesion synthesis past platinum-DNA adducts. Biochemistry 1999 Aug; 38 (34): 11026–39 Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996 Nov; 56 (21): 4881–6 Wei M, Cohen SM, Silverman AP, et al. Effects of spectator ligands on the specific recognition of intrastrand platinum-DNA cross-links by high mobility group box and TATA-binding proteins. J Biol Chem 2001 Oct; 276 (42); 38774–80 Twentyman PR, Wright KA, Mistry P, et al. Sensitivity to novel platinum compounds of panels of human lung-cancer cell-lines with acquired and inherent resistance to cisplatin. 1992 Oct; 52 (20): 5674–80 Kelland LR, Abel G, McKeage MJ, et al. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res 1993 Jun;53 (11): 2581–6 Wosikowski K, Caligiuri M, Lamphere L, et al. Efficacy of satraplatin, an oral platinum analogue in prostate cancer: synergistic activity with docetaxel [abstract no. 351]. ASCO Prostate Cancer Symposium; 2006 Feb 24–26; San Francisco (CA) Mellish KJ, Kelland LR, Harrap KR. In-vitro platinum drug chemosensitivity of human cervical squamous-cell carcinoma cell-lines with intrinsic and acquired-resistance to cisplatin. Br J Cancer 1993 Aug; 68 (2): 240–50 McKeage MJ, Kelland LR, Boxall FE, et al. Schedule dependency of orally-administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in-vivo. Cancer Res 1994 Aug; 54 (15): 4118–22 Wosikowski K. Efficacy of satraplatin (JM-216) and its metabolites is maintained in taxane-resistant tumors. 1st Conference on Cancer Therapeutics-Molecular Targets, Pharmacology and Clinical Applications, International Chemotherapy Society; 2004 Feb 19–21; Florence Rose WC. Combination chemotherapy involving orally administered etoposide and JM-216 in murine tumor models. Cancer Chemother Pharmacol 1997 May; 40 (1): 51–6 Amorino GP, Mohr PJ, Hercules SK, et al. Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapy. Cancer Chemother Pharmacol 2000 Nov; 46 (5): 423–6 Lamphere L, Obermayr F, Caligiuri M, et al. Satraplatin, an oral platinum analogue, is active and synergistic with paclitaxel and docetaxel in prostate cancer models [abstract no. 14620]. ASCO Annual Meeting; 2006 Jun 2–6; Atlanta (GA) McKeage MJ, Mistry P, Ward J, et al. A phase-I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 1995 Oct; 36 (6): 451–8 Beale P, Raynaud F, Hanwell J, et al. Phase I study of oral JM216 given twice daily. Cancer Chemother Pharmacol 1998 Jul; 42 (2): 142–8 McKeage MJ, Raynaud F, Ward J, et al. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 1997 Jul; 15 (7): 2691–700 Kurata T, Tamura T, Sasaki Y, et al. Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum (JM216) administered once a day for five consecutive days: a phase I study. Jpn J Clin Oncol 2000 Sep; 30 (9): 377–84 Sessa C, Minoia C, Ronchi A, et al. Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days. Ann Oncol 1998 Dec; 9 (12): 1315–22 Carr JL, Tingle MD, McKeage MJ. Rapid biotransformation of satraplatin by human red blood cells in vitro. Cancer Chemother Pharmacol 2002 Jul; 50 (1): 9–15 Raynaud FI, Mistry P, Donaghue A, et al. Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemother Pharmacol 1996 Jun; 38 (2): 155–62 Poon GK, Mistry P, Raynaud FI, et al. Determination of metabolites of a novel platinum anticancer drug JM216 in human plasma ultrafiltrates. J Pharm Biomed Anal 1995 Nov; 13 (12): 1493–8 Galettis P, Carr JL, Paxton JW, et al. Quantitative determination of platinum complexes in human plasma generated from the oral antitumour drug JM216 using directly coupled high-performance liquid chromatography-inductively coupled plasma mass spectrometry without desolvation. J Anal Atom Spectrom 1999 Jun; 14 (6): 953–6 Berners-Price SJ, Appleton TG. The chemistry of cisplatin in aqueous solution. In: Kelland LR, Farrell NP, editors. Platinum-based drugs in cancer therapy. Totowa (NJ): Humana Press, 2000: 3–36 Carr JL, Tingle MD, McKeage MJ. Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro. Cancer Chemother Pharmacol 2006 Apr; 57 (4): 483–90 Jones S, Hainsworth J, Burris HA, et al. Phase I study of JM-216 (an oral platinum analogue) in combination with paclitaxel in patients with advanced malignancies. Invest New Drugs 2002 Feb; 20 (1): 55–61 DeMario MD, Ratain MJ, Vogelzang NJ, et al. A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days. Cancer Chemother Pharmacol 1999 May; 43 (5): 385–8 George CM, Haraf DJ, Mauer AM, et al. A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest. Invest New Drugs 2001; 19: 10 Cmelak A, Choy H, Murphy B, et al. Phase I study of JM-216 with concurrent radiation in non-small cell lung cancer and squamous cell head and neck cancer [abstract no. 1520]. ASCO Annual Meeting; 1999 May 15–18; Atlanta (GA) American Cancer Society. Cancer facts and figures 2005 [online]. Available from URL: http://www.cancer.org/downloads/STT/CAFF2005f4PWSecured.pdf [Accessed 2007 Mar 16] Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer Suppl 1993; 71 (3): 1098–109 Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004 Oct; 351 (15): 1513–20 Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 Oct; 351 (15): 1502–12 Sternberg CN, Whelan P, Hetherington J, et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005; 68 (1): 2–9 Latif T, Wood L, Connell C, et al. Phase II study of oral bis (acetato) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC). Invest New Drug 2005 Jan; 23 (1): 79–84 Fokkema E, Groen HJM, Bauer J, et al. Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell long cancer. J Clin Oncol 1999 Dec; 17 (12): 3822–7 Fokkema E, Lunenberg J, Putten JWG, et al. Randomized phase II study of oral JM216 versus intravenous (iv) cisplatin in non-small cell lung cancer (NSCLC): preliminary results [abstract no. 1858]. ASCO Annual Meeting; 1998 May 16–19; Los Angeles (CA) Judson I, Cerny T, Epelbaum R, et al. Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation. Ann Oncol 1997 Jun; 8 (6): 604–6 Trudeau M, Stuart G, Hirte H, et al. A phase II trial of JM-216 in cervical cancer: An NCICCTG study. Gynecol Oncol 2002 Feb; 84 (2): 327–31 Anonymous. A randomized phase II study of satraplatin (JM-216) or standard platinum therapy in patients with late relapses of epithelial ovarian cancer (CA 142-006). Bristol-Myers Squibb Report; 1998 Jun 9. Accession No. 910068667 Petrylak DP, Sartor O, Witjes F, et al. A phase III, randomized, doubled-blind trial of satraplatin and prednisone vs placebo and prednisone for patients with hormone refractory prostate cancer (HRPC) [abstract no. 145]. ASCO Prostate Cancer Symposium; 2007 Feb 22–24; Orlando (FL)